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Abstract: A two and a half year old spayed female Miniature Australian Shepherd 
presented to a Montana veterinary clinic with acute onset of anorexia, vomiting and 
depression. Two days prior, the dog was exposed to an algal bloom in a community lake. 
Within h, the animal became lethargic and anorexic, and progressed to severe depression 
and vomiting. A complete blood count and serum chemistry panel suggested acute 
hepatitis, and a severe coagulopathy was noted clinically. Feces from the affected dog were 
positive for the cyanobacterial biotoxin, microcystin-LA (217 ppb). The dog was 
hospitalized for eight days. Supportive therapy consisted of fluids, mucosal protectants, 
vitamins, antibiotics, and nutritional supplements. On day five of hospitalization, a bile 
acid sequestrant, cholestyramine, was administered orally. Rapid clinical improvement was 
noted within 48 h of initiating oral cholestyramine therapy. At 17 days post-exposure the 
dog was clinically normal, and remained clinically normal at re-check, one year  
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post-exposure. To our knowledge, this is the first report of successful treatment of canine 
cyanobacterial (microcystin) toxicosis. Untreated microcystin intoxication is commonly 
fatal, and can result in significant liver damage in surviving animals. The clinical success 
of this case suggests that oral administration of cholestyramine, in combination with 
supportive therapy, could significantly reduce hospitalization time, cost-of-care and 
mortality for microcystin-poisoned animals.  
Keywords: acute hepatitis; blue-green algae; cholestyramine; cyanobacteria; hepatotoxin; 
microsystin; poisoning; silibinin 
 
1. Introduction 
Death from microcystin intoxication has been reported in fish [1,2], birds [2,3], companion  
animals [4–6], livestock [7,8], wildlife [9,10] and humans [11,12], and significant blooms can cause 
widespread morbidity and mortality [13]. Microcystins are structurally diverse cyclic heptapeptides 
that are primarily considered as hepatotoxins [14], although the gastrointestinal tract, kidney and other 
organs are also susceptible to toxin-mediated damage [15]. Human and animal exposure to microcystin 
typically occurs through ingestion of contaminated water or food, or by licking contaminated fur.  
Figure 1. Algal bloom caused by the cyanobacterium Microcystis aeruginosa in Middle 
Foy Lake near Kalispell, Montana in September, 2010. Photograph courtesy of Nate Chute, 
Daily Inter Lake [16] (A); Confirmation of this bloom as M. aeruginosa microscopically 
(cell size 2–3 µm) and detection of high concentrations of the cyanobacterial hepatotoxin 
microcystin-LA in surface scum was performed by scientists at the University of 
California, Santa Cruz (B).  
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Figure 1. Cont. 
 
In this case report a two and a half year old 11.6 kg (25.5 lb) spayed female Miniature Australian 
Shepherd presented on 13 September  2010, to the Flathead Animal Clinic in Kalispell, Montana, with 
an acute onset of anorexia, vomiting and profound depression. Two days prior to hospitalization, the 
dog was with her owners at Middle Foy Lake, a small (14 ha (0.05 mi2)), shallow lake located near 
Kalispell, northwest Montana. Middle Foy Lake is located adjacent to a small housing development 
and is used for recreation and fishing, and it is periodically stocked with rainbow trout. On the day of 
this visit, Middle Foy Lake contained a prominent, bright green algal surface scum (Figure 1A). The 
dog walked through this algal scum, and was observed by the owners to be drinking the pond water 
and licking water and algal scum from her fur coat. Within h of exposure, lethargy and anorexia 
developed, and then rapidly progressed to severe depression and vomiting.  
2. Case Report 
At the time of hospitalization, the dog was vomiting, anorexic and depressed. She was afebrile,  
38.4 °C (101.2° F), with pink mucus membranes and a capillary refill time of <2 s. Abdominal 
palpation did not elicit pain, and no evidence of loose stool was noted. A complete blood count and 
serum chemistry panel revealed lymphopenia, thrombocytopenia and profound elevations of total 
bilirubin, alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (Table 1). Intravenous fluid 
therapy (IV) (0.9% sodium chloride) was initiated at 200 mL/h for twenty minutes, and then lowered 
to a maintenance rate of 30 mL/h (approximately 60 mL/kg/day (27.3 mL/lb/day)). Denosyl (Nutramax 
Laboratories, Inc., Edgewood, MD, USA), a nutritional supplement containing S-Adenosylmethionine 
(SAM-e) was administered (20 mg/kg (8.8 mg/lb), per os (PO), q 24 h). SAM-e (S-adenosylmethionine) is 
formed from methionine and adenosine triphosphate (ATP). It acts as a methyl group donor to 
facilitate cellular biochemical reactions and may help reduce cholestasis. Anti-inflammatory and 
analgesic activity has also been attributed to SAM-e. An attempt to assess clotting parameters was 
unsuccessful and resulted in severe hemorrhage at the venipuncture site. 
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Table 1. Clinical hematological and serum chemistry parameters in a dog following acute microcystin intoxication and initiation of oral 
cholestyramine therapy. 
 
Exposure to 
cyanobacteria  
Presented to 
clinic * 
Declining clinical 
condition 
Initiation of oral 
cholestyramine therapy 
Released to owners 
for home care 
Office recheck Office recheck * 
Timeline of events 
No. days post toxin exposure 0–24 h 2 days 6 days 7 days 10 days 17 days 117 days 
No. days of hospitalization Pre-admission 0 h 4 days 5 days 8 days Discharged Discharged 
Clinical symptoms † 
Depression 2 3 2 2 1 0 0 
Anorexia 2 3 3 3 1 0 0 
Vomiting 3 3 3 2 0 0 0 
Icterus 0 0 3 3 2 1 0 
Abnormal bleeding, hematemesis 0 3 3 3 0 0 0 
Complete blood count ‡ 
WBC (6–17 × 103/μL) - 10.37 12.45 17.27 a 19.33 a 8.63 9.6 
LYM (1–4.8 × 103/μL) - 0.77 b 1.89 2.23 2.94 2.66 3.42 
NEU (3–12 × 103/μL) - 8.79 8.94 13.27 a 14.83 a 4.94 4.92 
RBC (5.5–8.5 × 106/μL) - 7.93 5.35 b 4.85 b 6.5 6.88 8.16 
HGB (12–18 g/dL) - 17.8 11.7 b 10.7 b 15.4 14.8 18.6 a 
HCT (37%–55%) § - 51.43 34.58 (33) b 31.64 (31) b 43.40 (42) 44.67 52.72 (53) 
PLT (200–500 × 103/μL) - 29 b 18 b 29 b 116 b 309 215 
Reviewer comments 
 
Schistocytes 
Schistocytes codocytes 
echinocytes     
Serum chemistry panel ‡ 
ALB (2.5–4.4 g/dL) - 4 1.8 b 1.7 b 2.9 2.9 4.3 
ALP (20–150 U/L) - 294 a 621 a 465 a 472 a 290 a 150 
ALT (10–118 U/L) - NM 8205 a 5486 a 3640 a 835 a 42 
TOTAL BILI (0.1–0.6 mg/dL) - 7.3 a 12.3 a 13.6 a 8.0 a 1.8 a 0.2 
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Exposure to 
cyanobacteria  
Presented to 
clinic * 
Declining clinical 
condition 
Initiation of oral 
cholestyramine therapy 
Released to owners 
for home care 
Office recheck Office recheck * 
BUN (5–31 mg/dL) - 25 31 39 a 14 9 26 
CRE (0.3–1.4 mg/dL) - ICT 1.7 a 1.7 a 1.3 1.2 1.1 
PHOS (2.9–6.6 mg/dL) - 5 6.3 6.2 4.7 4.5 5.2 
GLU (60–110 mg/dL) - 97 87 88 93 92 104 
CA++ (8.6–11.8 mg/dL) - 11.1 8.3 b 8.4 b 10.2 10.5 11.2 
NA+ (138–160 mmol/L) - 139 142 145 147 145 143 
K+ (3.7–5.8 mmol/L) - 4.3 4.2 4 4.2 4.6 4.6 
CL− (110–118 mmol/L) - - 117 122 a 110 115 - 
AST (1–37 U/L) - - 1419 a 367 a 160 a 67 a - 
CK (25–467 U/L) - - 110 147 61 81 - 
CHOLESTEROL (126–359 mg/dL) - - 94 b 79 b 110 b 147 - 
Hemolyzed - 2+ - - - - 0 
Lipemic - 0 - - - - 1 
Icteric - 2+ - - - - 0 
* = blood samples analyzed in-clinic with VetScan HM5 Hematology Analyzer; all other blood chemistry values were determined by Kalispell Regional Medical Center Laboratory;  
† = Categories defined as: 0 = not detected; 1 = mild; 2 = moderate; 3 = severe; ‡ = values in parenthesis represent the normal range; § = Hematocrit values presented without parentheses are 
machine-derived, while values in parentheses were determined by hand for the same sample; a = above normal reference values; b = below normal reference values; NM = no measurement, 
values too high for machine to read; ICT = value supressed, results affected by >10% interference from icterus; - = information not available. 
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Over the next few days the dog’s condition continued to deteriorate. On the third day of 
hospitalization (five days post-exposure), the mucus membranes, sclera, and pinnae became markedly 
icteric. Dark yellow urine and tarry stools were also noted. The IV fluid was supplemented with  
20–32 m Eq/L of potassium chloride (KCl) and 5% Dextrose to correct for enteric potassium loss and 
continuing anorexia. Results from an IDEXX clotting profile came back as non-diagnostic due to a 
clotted sample. It was suspected that either the sample was roughly handled post-sampling, or that the 
animal was in a hypercoaguable state consistent with disseminated intravascular coagulation (DIC). 
On day four of hospitalization (six days post-exposure), repeated hematology and serum chemistry 
assays revealed progressive and severe elevations of total bilirubin, ALT, and ALP as well as high 
levels of aspartate aminotransferase (AST), reflective of severe hepatocellular injury and cholestasis. 
(Table 1). In addition, the dog was hypocalcemic, hypoproteinemic, hypoalbuminemic and 
hypocholesterolemic, with a mild elevation of serum creatinine. The serum was visibly icteric, with 
worsening thrombocytopenia (18,000 platelets per µL) and mild anemia. Occasional, codocytes, 
acanthocytes, and schistocytes were observed on blood smears, indicating liver disease and DIC. The 
dog remained severely depressed and anorexic and she continued to vomit and produce dark 
yellow/brown colored urine.  
Based on these discouraging findings, additional supportive measures were added, including 
vitamin B complex supplementation to help facilitate lipid metabolism (B1 25 mg, B2 4 mg, B3  
25 mg, B6 10 mg, B12 10 μg, IV, q 24 h), famotidine to minimize gastric ulceration and bleeding  
(0.5 mg/kg (0.23 mg/lb), SC, q 24 h), and procaine penicillin G to prevent septicemia resulting from 
decreased hepatic bacterial clearance (PPG 300,000 U/kg (136,364 u/lb), IM, q 24 h). The IV fluid 
infusion rate was increased to 60 mL/h to promote diuresis (120 mL/kg/day (54.5 mL/lb/day)) and oral 
SAM-e supplementation was continued. A considerable amount of hemorrhage was observed after 
intramuscular (IM) administration of PPG, so IV administration of penicillin G potassium was 
substituted (35,000 u/kg (15,910 u/lb), IV, q 24 h). Urine and blood samples were submitted for 
polymerase chain reaction (PCR) detection of Leptospira spp. Despite a somewhat brighter 
disposition, the dog remained icteric and continued to vomit during day five of hospitalization (seven 
days post-exposure). She developed hematemesis, and the color of vomitus ranged from bright red to 
brownish-black, indicative of a high content of undigested (red) and partially digested (black) blood 
within the gastric lumen. Hematology and serum chemistry assays revealed progressive increases in 
both total bilirubin and Blood Urea Nitrogen (BUN). The concentrations of ALT and ALP remained 
markedly elevated, although absolute values had decreased relative to the previous blood sample 
(Table 1). Also noted were continued mild anemia, mild leukocytosis and neutrophilia. Serum platelets 
had increased to 29,000 per µL, but still well below normal levels. The dog remained mildly 
hypocalcemic, hypoproteinemic, hypoalbuminemic, and hypocholesterolemic, with a mild elevation of 
serum creatinine. Based on these findings, the dog’s IV fluid infusion rate was returned to 30 mL/h. 
On day 5, after telephone consultation with the study co-authors, treatment with cholestyramine 
(Cholestyramine Light Packet (Sandoz, Princeton, NJ, USA), 172 mg/kg (78.4 mg/lb) mixed with 
water, PO, q 24 h) was initiated. This medication was added to the treatment regimen based on a 
previously published report that demonstrated the ability of oral cholestyramine to bind enteric 
cyanotoxins (microcystin-LR) in laboratory rats, thereby reducing toxin-related morbidity and 
mortality [17].  
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During the next two days, slow but progressive clinical improvement was observed. On day six of 
hospitalization, the dog’s temperament was bright, but she remained icteric and was only mildly 
interested in food. By the following day, vomiting had ceased, and the mucous membranes and sclera 
were pinker than on previous days. All medications were continued as before, with the addition of 
Denamarin (Pfizer Animal Health, New York, NY, USA) on day six (SAM-e 20 mg/kg (8.8 mg/lb) 
plus silibinin 2 mg/kg (0.94 mg/lb), PO, q 24 h) and supplementary thiamine (8.6 mg/kg (4.0 mg/lb), 
IV, q 24 h) on day seven to address potential deficiencies due to continued anorexia. Additionally, on 
day six of hospitalization (day 8 post-exposure), fresh feces from the affected dog were submitted to 
the University of California, Santa Cruz for cyanotoxin screening via liquid chromatography/mass 
spectrophometry (LC/MS). Surface scum collected from the ongoing algal bloom at Middle Foy Lake 
was also submitted for microscopic examination and LC/MS testing.  
By day seven of hospitalization, the icterus was resolving, vomiting had ceased and the dog was 
eating small amounts of food. The Leptospira spp. PCR results were negative. A complete blood count 
and serum chemistry panel revealed significant improvements in total bilirubin, ALT and ALP 
concentrations and an increased platelet count (Table 1). On day eight, intravenous fluids were 
discontinued and the animal was discharged with instructions to rest and recheck bloodwork in  
5–7 days. Oral cholestyramine and Denamarin (SAM-e and silibinin) therapy were continued at home 
at the same dosages for 14 days following hospital discharge. Additionally, famotidine (0.4 mg/kg  
(0.2 mg/lb), PO, q 24 h), amoxicillin (20 mg/kg (9.1 mg/lb), PO, q 12 h), and an iron-rich vitamin 
supplement (Lixotinic, 6 mL, PO, q 24 h) were prescribed. For the subsequent 5–6 weeks, the dog was 
maintained on a diet of Hills l/d, a prescription diet formulated for hepatic support.  
The dog presented to the clinic one week later for follow-up evaluation. While slight icterus was 
still detectable, all other clinical abnormalities had resolved, with no vomiting noted since leaving the 
hospital. The platelet count had returned to normal, and the total bilirubin and liver enzyme values were 
greatly reduced. During a recheck examination four months post-exposure, the complete blood count 
and serum chemistry panel findings were unremarkable and no clinical abnormalities were noted.  
Surface scum collected by the study co-authors from Middle Foy Lake during the bloom event 
contained 38,627 ppb microcystin-LA, and large numbers of cyanobacteria compatible with 
Microcystis aeruginosa were observed in this same sample via light microscopy. Feces from the 
exposed dog collected eight days post-exposure also contained 217 ppb of microcystin-LA. The 
microcystin congeners -LR, -RR, and -YR were not detected at appreciable levels in these samples, nor 
was there any indication of other microcystin congeners, based on total ion chromatograms. After the 
treating DVM (Rankin) reported her findings to local public health authorities, they issued a press 
release regarding potential animal and human health risks associated with water contact at the lake. 
This notification also catalyzed efforts to provide ongoing surveillance, and mitigate toxic cyanobacterial 
blooms at this site by the local community.  
3. Discussion  
To the author’s knowledge, this is the first description of successful treatment of  
biochemically-confirmed cyanobacterial (microcystin-LA) toxicosis in a dog. Based on published 
reports [4–6,8,18], most affected animals die or are euthanized due to the severity of their disease, a 
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perceived lack of efficacious treatment options and the high cost of prolonged supportive care. 
However, our results describing expedited recovery of a microcystin-poisoned dog, as well as prior 
laboratory studies, suggest that oral cholestyramine administration could reduce treatment costs, 
shorten recovery times and enhance patient survival. Toxin removal from the gastrointestinal tract and 
aggressive supportive care, including IV fluid therapy are core therapeutic measures. Other critical 
steps include preventing access to contaminated water and washing exposed animals to remove 
residual toxin from their fur [19]. Supplementation with B vitamins may also help support liver 
function, as well as the induction of emesis or oral administration of activated charcoal to minimize 
microcystin absorption and enterohepatic recirculation [5].  
The dog reported in this study exhibited dark tarry stools and abnormal bleeding. It is unknown 
which of the following were the primary contributors to the observed coagulopathy: severe hepatic 
damage leading to depletion of hepatogenic clotting factors, vascular mural or endothelial damage, 
cyanobacterial lipopolysaccharide endotoxicosis, impaired function of clotting factors, red blood cells 
or platelets, clinically confirmed thrombocytopenia, secondary shock and/or disseminated intravascular 
coagulation. For severe cyanobacterial intoxication, blood, plasma or platelet transfusions may be 
necessary [19]. A multi-modal therapeutic approach was utilized in this case, including IV fluids, 
mucosal protectants, vitamins, antibiotics, nutritional supplementation and oral application of 
cholestyramine and silibinin; two therapeutic agents with reported hepatoprotective properties. To the 
author’s knowledge, no prior studies have described the clinical application of these two compounds 
for treatment of microcystin intoxication in naturally occurring cases. 
Cholestyramine is a non-digestible ion exchange resin that binds bile in the gastrointestinal tract 
and prevents enterohepatic recirculation of bile acids and associated bound substances. In humans it 
has been used to treat hypercholesterolemia and cholestatic pruritis (from 50 mg/kg (22.7 mg/lb) to 
200 mg/kg (91 mg/lb), PO, q 24h) [20]. It has also been used to treat humans with Possible  
Estuarine-Associated Syndrome (112 mg/kg (51 mg/lb) PO, q 6 h), a syndrome caused by ingestion of 
toxins from the dinoflagellate (Pfiesteria) [21]. Cholestyramine can bind >99% of microcystin-LR [17]  
in vitro, and in vivo studies in rats have confirmed that cholestyramine binds microcystin-LR in the 
gastrointestinal lumen. When intra-intestinal cholestyramine (175–550 mg/kg (80–250 mg/lb)) was 
administered immediately following experimental intra-intestinal administration of microcystin-LR 
(2.5–5 mg/kg (1.1–2.3 mg/lb)) in rats, only mild hepatocyte rounding was observed, in contrast to 
severe hepatocyte degeneration and necrosis in rats that received the same dose of microcystin without 
cholestyramine [17].  
In humans, oral administration of high doses of cholestyramine (200–250 mg/kg (91–114 mg/lb), 
PO, q 24 h) is associated with bloating, constipation, nausea and flatulence [21]. Cholestyramine may 
also impair intestinal absorption of other medications. To minimize this effect, it should be administered 
one hour before, or 4 h following meals or administration of other oral medications [21]. The 
microcystin-poisoned dog was treated at a lower dose (172 mg/kg (78 mg/lb), PO, q 24 h) and no new 
clinical abnormalities were observed after cholestyramine administration was initiated.  
The dog was also treated with an oral supplement (Denamarin, Sigma Aldrich Corporation, St. 
Louis, MO, USA) that contains 225 mg of SAM-e (an antioxidant) and 24 mg of silibinin. Silibinin is 
the major active ingredient of milk thistle (Silybum marianum) extract, (also known as Silymarin), a 
mixture of flavonolignans, including silibinin A and B, isosilibinin A and B, silicristin and silidianin. 
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In vitro and in vivo studies suggest that silymarin and silibinin have antihepatotoxic  
properties [22–25], and silymarin may help neutralize the hepatotoxic effects of ethanol, 
acetaminophen, and amatoxins produced by toxic mushrooms, including Amanita phalloides [24]. 
Lakshamana Rao et al. [25] demonstrated that intraperitoneal pre-treatment with silymarin (400 mg/kg 
(181 mg/lb) IP) in mice is protective against microcystin-LR toxicity. Intraperitoneal (IP) 
administration of microcystin-LR (0.1 mg/kg (0.05 mg/lb)) alone resulted in 100% mortality in mice, 
while IP treatment with silymarin at 3 and 24 h before microcystin administration resulted in 0% 
mortality [25]. Mereish et al. [22] also reported that intraperitoneal pre-treatment with silymarin  
(150–500 mg/kg (68–227 mg/lb), IP) in rats reduced mortality due to microcystin-LR toxicity, but  
pre-treatment was less efficacious at lower dosages (150–350 mg/kg (68–160 mg/lb), IP).  
In contrast with IP therapy, oral pre-treatment with silymarin, even at high doses (500 mg/kg  
(227 mg/lb), PO), did not prevent microcystin toxicity in rats, with 100% mortality observed [23]. The 
medical literature also documents poor bioavailability of oral silymarin in humans [24]. To date, 
studies examining the clinical efficacy of silibinin and silymarin have been difficult to interpret due 
small sample sizes and variations in research objectives, dosage, routes of administration and extract 
composition [24]. In addition, the dosage of oral silibinin administered in this case (2 mg/kg  
(0.94 mg/lb), PO, q 24 h) was much lower and less frequent than those from published reports. While 
silibinin may have contributed to this dog’s recovery in some capacity, the conservative dosage and 
oral route of administration were unlikely to have strongly influenced clinical outcome, based on 
published findings in other species.  
Although a controlled study was not possible, the temporal association between initiation of oral 
cholestyramine therapy and the onset and speed of clinical and hematological recovery is striking in 
this case. Cholestyramine therapy was initiated six days post-exposure after a long period of 
worsening, or at best, static condition. Notable clinical improvement was appreciated after 48 h and by 
the third day of cholestyramine therapy, significant improvements in platelet counts, hematocrit and 
total bilirubin were also detected (Table 1). This dog went on to make a full clinical recovery, with 
normalization of all blood values, and she remains clinically normal one year post-exposure. 
Experimental studies in combination with these clinical findings appear to support the efficacy of 
cholestyramine as a treatment of microcystin intoxication. Combination therapy of both 
cholestyramine and silibinin might further improve clinical outcome, however, higher silibinin dosages 
and/or parenteral administration would probably be necessary. More robust studies of the efficacy of 
cholestyramine and/or silibinin for treating human and animal intoxication by microcystin and other 
cyanotoxins are warranted. 
Unfortunately, rapid, inexpensive, and widely accessible assays are not currently available to 
facilitate rapid diagnosis and treatment of cyanobacterial intoxication. Many commercial diagnostic 
laboratories offer few or no diagnostic tests for cyanotoxin detection, so clinicians wishing to perform 
cyanotoxin testing should consult with federal, state and academic toxicology laboratories. The gold 
standard tests for toxin identification and characterization are currently LC/MS, gas chromatography/mass 
spectrophotometry, or liquid chromatography combined with tandem spray mass spectrophotometry [12]. 
Cyanotoxins can be detected in liver, bile, feces, urine, and serum, but samples should be kept at ≤4 °C 
(39.2° F) if stored for prolonged periods prior to testing [9,12,26]. Microcystins are relatively stable, 
once formed, and have been detected in tissues stored for >10 years at −70 °C [12]. Based on limited 
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testing of known-positive otters, liver, bile and feces appear to be optimal samples for postmortem 
microcystin detection, while feces, digesta and vomitus could be used for screening live animals. 
However, based on biochemical tests of a number of sea otters that were microcystin-positive on 
LCMS/MS tests of liver, feces and/or bile, serum proved to be a comparatively insensitive sample 
matrix that often yielded false negative results [27]. Because of this insight regarding test performance 
and due to cost constraints, serum testing for microcystin was not attempted in this case. A publication 
detailing test results in different sample matrices for sea otters is in preparation. Bioassays have also 
been used to confirm diagnosis by injecting laboratory mice with suspect material (1.0 mL IP) [5,7].  
In the current study, the presence of a toxic cyanobacterial bloom at Middle Foy Lake was 
confirmed both microscopically and biochemically (Figure 1B). Both surface scum from the lake and 
feces from the exposed dog tested positive for microcystin-LA at 38,627 and 217 ppb, respectively. 
The concentration of microcystin-LA detected in algal scum from Middle Foy Lake was nearly  
4000 times the World Health Organization advisory level for recreational exposure, and almost  
40,000 times the established limit for microcystin contamination of finished drinking water [14]. In 
humans, microcystin exposure can cause dermatitis, ophthalmitis, ataxia, acute gastroenteritis and, 
rarely, severe hepatic injury or death [28]. Chronic exposure to cyanobacterial toxins in humans has 
been linked to development of primary liver cancer and neurodegenerative disease [29,30].  
Through rapid recognition, treatment and reporting of cyanotoxin poisoning cases, veterinarians can 
help prevent animal deaths, limit human and animal exposure, and promote mitigation of 
cyanobacterial blooms in nutrient-impaired water bodies. Because microcystins are regulated 
pollutants that can cause illness and death in humans, opportunities for catalyzing environmental 
mitigation are substantial. At present there is a significant unmet need for simple and inexpensive 
diagnostic tests to expedite diagnosis and treatment for humans, domestic animals and wildlife that 
have been poisoned by cyanotoxins. Once these tests are more widely available, we predict that case 
recognition will increase dramatically throughout North America and worldwide. In addition, both the 
quality and success of clinical care, and efforts to control and prevent cyanobacterial blooms can be 
expected to make significant advances.  
4. Conclusions 
This manuscript provides the first report of successful treatment of canine cyanobacterial 
(microcystin) toxicosis. Untreated microcystin intoxication is commonly fatal. The clinical success of 
this case suggests that administration of cholestyramine, in combination with supportive care could 
significantly reduce morbidity and mortality due to microcystin intoxication. In addition to improving 
survival rates for affected animals, oral cholestyramine therapy may also shorten the clinical course of 
microcystin intoxication, thus decreasing veterinary costs and ensuring that more animals receive 
veterinary care post-exposure. Veterinarians can help prevent additional animal deaths and expedite 
mitigation of cyanobacterial blooms by reporting suspect and confirmed cases to local public health 
and water quality officials.  
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